FDA slaps a clinical hold on Achillion hep C drug

Shares of Achillion ($ACHN) skidded down 20% as the FDA put a clinical hold on its hepatitis C drug sovaprevir. Investigators had flagged a spike in liver enzymes--a classic sign of toxicity--among a group of patients taking it in a combo treatment. Report